Evidence map›Paper›PMID 20348231›Full record

ArticleToxicological sciences : an official journal of the Society of Toxicology2010

2,3,7,8-tetrachlorodibenzo-p-dioxin-mediated suppression of toll-like receptor stimulated B-lymphocyte activation and initiation of plasmacytic differentiation.

Colin M North, Robert B Crawford, Haitian Lu, Norbert E Kaminski

Abstract read
In one paragraph

Article in Toxicological sciences : an official journal of the Society of Toxicology, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.

0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed
0.9field-weighted citation impact, top 25% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

15 citing papers in PubMed, 25 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Epigenetic Regulations of AhR in the Aspect of Immunomodulation.International journal of molecular sciences · 2020
    Review
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Review
  15. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 1 institution in 1 country.

Colin M NorthCenter for Integrative Toxicology, Department of Pharmacology & Toxicology, Michigan State University, East Lansing, Michigan 48824, USA.
Robert B Crawford
Haitian Lu
Norbert E Kaminski
Michigan State University · US

Funding

VOLATILE ORGANIC CONTAMINANTS--QUANTIFYING THEIR MOVEMENT IN THE UNSATURATED ZONEP42ES004911 · NIEHS · MICHIGAN STATE UNIVERSITY · PI Timothy R. Zacharewski · 1989 to 2026
$64.9M
MULTIDISCIPLINARY TRAINING IN ENVIRONMENTAL TOXICOLOGYT32ES007255 · NIEHS · MICHIGAN STATE UNIVERSITY · PI JOHN J LAPRES · 1989 to 2026
$9.3M
TOXIC EFFECTS OF TCDD ON B CELLSR01ES002520 · NIEHS · VIRGINIA COMMONWEALTH UNIVERSITY · PI KAMINSKI, NORBERT E · 1986 to 2016
$4.2M
NIEHS NIH HHS P42 ES004911NIEHS NIH HHS P42 ES04911NIEHS NIH HHS R01 ES002520NIEHS NIH HHS R01 ES02520NIEHS NIH HHS T32 ES007255NIEHS NIH HHS T32 ES07255
6 · The paper itself

Abstract

2,3,7,8-Tetrachlordibenzo-p-dioxin (TCDD) is a potent suppressor of humoral immunity, disrupting antibody production in response to both T cell-dependent and T cell-independent antigens. Among the cell types required for humoral responses, the B cell is highly, and directly, sensitive to TCDD. B cells become antibody-secreting cells via plasmacytic differentiation, a process regulated by several transcription factors, including activator protein-1, B-cell CLL/lymphoma 6 (BCL-6), and B lymphocyte-induced maturation protein 1 (Blimp-1). The overarching conceptual framework guiding experimentation is that TCDD disrupts plasmacytic differentiation by altering the expression or activity for upstream regulators of Blimp-1. Multiparametric flow cytometry was used to investigate TCDD-induced alterations in both activation marker and transcription factor expression following lipopolysaccharide (LPS) activation of purified B cells. TCDD significantly impaired LPS-activated expression of major histocompatibility complex class II, cluster of differentiation (CD)69, CD80, and CD86. Immunosuppressive concentrations of TCDD also suppressed LPS-activated Blimp-1 and phosphorylated c-Jun expression, whereas elevating BCL-6 expression. Because BCL-6 and c-Jun are directly and indirectly regulated by the kinases AKT, extracellular signal-regulated kinase (ERK), and Jun N-terminal kinase (JNK), it was hypothesized that TCDD alters toll-like receptor-activated kinase phosphorylation. TCDD at 0.03 and 0.3 nM significantly impaired phosphorylation of AKT, ERK, and JNK in CH12.LX B cells activated with LPS, CpG oligonucleotides, or resiquimod (R848). In primary B cells, R848-activated phosphorylation of AKT, ERK, and JNK was also impaired by TCDD at 30 nM. These results suggest that impairment of plasmacytic differentiation by TCDD involves altered transcription factor expression, in part, by suppressed kinase phosphorylation.

Indexed as

AnimalsBase SequenceB-LymphocytesCell DifferentiationCell LineEnzyme-Linked Immunosorbent AssayFemaleLymphocyte ActivationMiceMice, Inbred C57BLOligonucleotidesPhosphorylationPolychlorinated DibenzodioxinsToll-Like ReceptorsTranscription FactorsOligonucleotidesPolychlorinated DibenzodioxinsToll-Like ReceptorsTranscription Factors

Identifiers

PMID20348231
PMCPMC2886857
OpenAlexW2124604472

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.